The role of micronutrients in the risk of urinary tract cancer

Archives of Medical Science

Volumn 12, Issue 2, 2016, Pages 436-447

  Golabek, Tomasz ^a   Bukowczan, Jakub ^b   Sobczynski, Robert ^c   Leszczyszyn, Jaroslaw ^d   Chlosta, Piotr L ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^d EMC Health Care Clinic   (Ireland)

Author keywords

Bladder cancer; Elements; Kidney cancer; Prostate cancer; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; RETINOL; SELENIUM; VITAMIN; VITAMIN B GROUP; VITAMIN D; ZINC;

ARTICLE; BLADDER CANCER; CANCER RISK; CARCINOGENESIS; HUMAN; KIDNEY CANCER; NUTRIENT; PROSTATE CANCER; URINARY TRACT CANCER; VITAMIN SUPPLEMENTATION;

EID: 84963780701     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2016.59271     Document Type: Article

References (112)

1. Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008; 101: 11-9.
2. Levi F, Ferlay J, Galeone C, et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008; 101: 949-58.
3. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-52.
4. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 2011; 60: 1-15.
5. Zaborowska M, Szmit S, Szczylik C. Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option? Arch Med Sci 2012; 8: 528-32.
6. Pikala M, Maniecka-Bryla I. Years of life lost due to malignant neoplasms characterized by the highest mortality rate. Arch Med Sci 2014; 10: 999-1006.
7. Golabek T, Darewicz B, Borawska M, Markiewicz R, So-cha K, Kudelski J. Lead concentration in the bladder tissue and blood of patients with bladder cancer. Scand J Urol Nephrol 2009; 43: 467-70.
8. Golabek T, Darewicz B, Borawska M, Socha K, Mar-kiewicz R, Kudelski J. Copper, zinc, and Cu/Zn ratio in transitional cell carcinoma of the bladder. Urol Int 2012; 89: 342-7.
9. Golabek T, Powroznik J, Chłosta P, Dobruch J, Borów-ka A. The impact of nutrition in urogenital cancers. Arch Med Sci 2015; 11: 411-8.
10. Golabek T, Bukowczan J, Chłosta P, Powroznik J, Do-bruch J, Borówka A. Obesity and prostate cancer incidence and mortality: a systematic review of prospective cohort studies. Urol Int 2014; 92: 7-14.
11. Sandhu GS, Nepple KG, Tanagho YS, Andriole GL. Prostate cancer chemoprevention. Semin Oncol 2013; 40: 276-85.
12. Erdurak K, Dundar PE, Ozyurt BC, Negri E, La Vecchia C, Tay ZL. Smoking, occupation, history of selected diseases and bladder cancer risk in Manisa, Turkey. Eur J Cancer Prev 2014; 23: 58-61.
13. Piastowska-Ciesielska AW, Kozłowski M, Wagner W, Dominska K, Ochedalski T. Efect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells. Arch Med Sci 2013; 9: 739-44.
14. Golabek T, Darewicz B, Kudelski J, et al. Cadmium in urothelial carcinoma of the bladder. Pol J Pathol 2014; 65: 55-9.
15. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer and cardiovascular disease in the women's health initiative cohorts. Arch Intern Med 2009; 169: 294-304.
16. McGinnis JM, Birt D F, Brannon PR, et al. National Institutes of Health State-of-the-Science Conference Statement: multivitamin/mineral supplements and chronic disease prevention. Ann Intern Med 2006; 145: 364-71.
17. Neuhouser ML, Patterson RE, Levy L. Motivations for using vitamin and mineral supplements. J Am Diet Assoc 1999; 99: 851-4.
18. Fritz H, Kennedy D, Fergusson D, et al. Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta-analysis. PLoS One 2011; 6: e21107.
19. Donkena KV, Karnes RJ, Young CY. Vitamins and prostate cancer risk. Molecules 2010; 15: 1762-83.
20. Lee JE, Giovannucci E, Smith-Warner SA, Spiegel-man D, Willett WC, Curhan GC. Intakes of fruits, vegetables, vitamins A, C, and E, and carotenoids and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2445-52.
21. Studer UE, Jenzer S, Biedermann C, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superfcial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28: 284-90.
22. Prout GR Jr, Barton BA. 13-cis-retinoic acid in chemo-prevention of superfcial bladder cancer. The National Bladder Cancer Group. J Cell Biochem Suppl. 1992; 16: 148-52.
23. Schuurman AG, Goldbohm RA, Brants HAM, Van Den Brandt PA. A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes Control 2002; 13: 573-82.
24. Mondul AM, Watters JL, Männistö S, et al. Serum reti-nol and risk of prostate cancer. Am J Epidemiol 2011; 173: 813-21.
25. Power ML, Heaney R P, Kalkwarf HJ, et al. The role of calcium in health and disease. Am J Obstet Gynecol 1999; 181: 1560-9.
26. Bers DM. Calcium cycling and signaling in cardiac my-ocytes. Annu Rev Physiol 2008; 70: 23-49.
27. Ross AC, Taylor CL, Yaktine AL, Del Vall HB. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.
28. Qin LQ, Xu JY, Wang PY, Kaneko T, Hoshi K, Sato A. Milk consumption is a risk factor for prostate cancer: meta-analysis of case-control studies. Nutr Cancer 2004; 48: 22-7.
29. Dagnelie PC, Schuurman AG, Goldbohm RA, Van Den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 2004; 93: 1139-50.
30. Gao X, LaValley M P, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 2005; 97: 1768-77.
31. Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 2005; 8: 304-10.
32. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 203-10.
33. Tavani A, Bertuccio P, Bosetti C, et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 2005; 48: 27-33.
34. Moukayed M, Grant WB. Molecular link between vitamin D and cancer prevention. Nutrients 2013; 5: 3993-4021.
35. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feld-man BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014; 14: 342-57.
36. Wacker M, Holick MF. Sunlight and vitamin D: a global perspective for health. Dermatoendocrinol 2013; 5: 51-108.
37. Garland C F, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252-61.
38. Kricker A, Armstrong B. Does sunlight have a benefcial infuence on certain cancers? Prog Biophys Mol Biol 2006; 92: 132-9.
39. van der Rhee HJ, de Vries E, Coebergh JW. Does sunlight prevent cancer? A systematic review. Eur J Cancer 2006; 42: 2222-32.
40. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861-9.
41. Schwartz GG, Hanchette CL. U V, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 2006; 17: 1091-101.
42. Grant WB. Geographic variation of prostate cancer mortality rates in the United States: implications for prostate cancer risk related to vitamin D. Int J Cancer 2004; 111: 470-1.
43. Gilbert R, Metcalfe C, Oliver SE, et al. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int J Cancer 2009; 125: 414-23.
44. Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26, 769 cases from 45 observational studies. Nutr Cancer 2008; 60: 421-41.
45. Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 2011; 22: 319-40.
46. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-inde-pendent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008; 112: 326-30.
47. Mohr SB, Gorham ED, Garland C F, Grant WB, Garland FC. Are low ultraviolet B and high animal protein intake associated with risk of renal cancer? Int J Cancer 2006; 119: 2705-9.
48. Gallicchio L, Helzlsouer KJ, Chow WH, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172: 10-20.
49. Mellemgaard A, McLaughlin JK, Overvad K, Olsen JH. Dietary risk factors for renal cell carcinoma in Denmark. Eur J Cancer 1996; 32A: 673-82.
50. Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1997; 8: 31-6.
51. Bosetti C, Scotti L, Maso LD, et al. Micronutrients and the risk of renal cell cancer: a case-control study from Italy. Int J Cancer 2007; 120: 892-6.
52. Wilson RT, Wang J, Chinchilli V, et al. Fish, vitamin D, and favonoids in relation to renal cell cancer among smokers. Am J Epidemiol 2009; 170: 717-29.
53. Obara W, Suzuki Y, Kato K, Tanji S, Konda R, Fujioka T. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int J Urol 2007; 14: 483-7.
54. Karami S, Brennan P, Rosenberg PS, et al. Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS One 2009; 4: e7013.
55. Hermann GG, Andersen CB. Transitional cell carcinoma express vitamin D receptors. Scand J Urol Nephrol 1997; 31: 161-6.
56. Konety BR, Lavelle J P, Pirtskalaishvili G, et al. Efects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001; 165: 253-8.
57. Mondul AM, Weinstein SJ, Männistö S, et al. Serum vitamin D and risk of bladder cancer. Cancer Res 2010; 70: 9218-23.
58. Mondul AM, Weinstein SJ, Horst RL, Purdue M, Alba-nes D. Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial. Cancer Epidemiol Biomarkers Prev 2012; 21: 1222-5.
59. Jiang Q. Natural forms of vitamin E: metabolism, an-tioxidant, and anti-infammatory activities and their role in disease prevention and therapy. Free Radic Biol Med 2014; 72C: 76-90.
60. Rizvi S, Raza ST, Ahmed F, Ahmad A, Abbas S, Mahdi F. The role of vitamin E in human health and some diseases. Sultan Qaboos Univ Med J 2014; 14: e157-65.
61. Fleshner N, Fair WR, Huryk R, Heston WDW. Vitamin E inhibits the high-fat diet promoted growth of established human prostate lncap tumors in nude mice. J Urol 1999; 161: 1651-4.
62. Heinonen O P, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440-6.
63. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8: 893-9.
64. Santillo VM, Lowe FC. Role of vitamins, minerals and supplements in the prevention and management of prostate cancer. Int Braz J Urol 2006; 32: 3-14.
65. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligo-nucleotide array. Cancer Res 2003; 63: 52-9.
66. Tos-Luty S, Obuchowska-Przebirowska D, Latuszyn-ska J, Musik I, Tokarska-Rodak M. Comparison of his-tological and ultrastructural changes in mice organs after supplementation with inorganic and organic selenium. Ann Agric Environ Med 2003; 10: 87-91.
67. Klein EA, Thompson IM. Chemoprevention of prostate cancer: an updated view. World J Urol 2012; 30: 189-94.
68. Clark LC, Combs GF Jr, Turnbull BW, et al. Efects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276: 1957-63.
69. Lippman SM, Klein EA, Goodman PJ, et al. Efect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009; 301: 39-51.
70. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
71. Algotar AM, Stratton MS, Ahmann FR, et al. Phase 3 clinical trial investigating the efect of selenium supplementation in men at high-risk for prostate cancer. Prostate 2013; 73: 328-35.
72. Kwiatek WM, Drewniak T, Gajda M, Gałka M, Hanson AL, Cichocki T. Preliminary study on the distribution of selected elements in cancerous and non-cancerous kidney tissues. J Trace Elem Med Biol 2002; 16: 155-60.
73. Meyer HA, Endermann T, Stephan C, et al. Selenopro-tein P status correlates to cancer-specifc mortality in renal cancer patients. PLoS One 2012; 7: e46644.
74. Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 1995; 87: 497-505.
75. Bardia A, Tleyjeh IM, Cerhan JR, et al. Efcacy of anti-oxidant supplementation in reducing primary cancer incidence and mortality: systematic review and me-ta-analysis. Mayo Clin Proc 2008; 83: 23-34.
76. Roswall N, Olsen A, Christensen J, Dragsted LO, Over-vad K, Tjønneland A. Micronutrient intake and risk of urothelial carcinoma in a prospective Danish Cohort. Eur Urol 2009; 56: 764-70.
77. Jacobs EJ, Henion AK, Briggs PJ, et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 2002; 156: 1002-10.
78. Lotan Y, Goodman PJ, Youssef R F, et al. Evaluation of vitamin e and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. J Urol 2012; 187: 2005-10.
79. Hu J, Mao Y, White K; Canadian Cancer Registries Epidemiology Research Group. Diet and vitamin or mineral supplements and risk of renal cell carcinoma in Canada. Cancer Causes Control 2003; 14: 705-14.
80. Nicodemus KK, Sweeney C, Folsom AR. Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. Int J Cancer 2004; 108: 115-21.
81. Hu J, La Vecchia C, Negri E, DesMeules M, Mery L. Canadian Cancer Registries Epidemiology Research G. Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma. Cancer Causes Control 2009; 20: 1451-8.
82. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
83. Lin HL, An QZ, Wang QZ, Liu CX. Folate intake and pancreatic cancer risk: an overall and dose-response meta-analysis. Public Health 2013; 127: 607-13.
84. Ho E, Beaver LM, Williams DE, Dashwood RH. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr 2011; 2: 497-510.
85. Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer 2005; 113: 819-24.
86. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-81.
87. Collin SM, Metcalfe C, Refsum H, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and me-ta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1632-42.
88. Ulrich CM, Grady WM. Linking epidemiology to epig-enomics-where are we today? Cancer Prev Res (Phila) 2010; 3: 1505-8.
89. Vlajinac HD, Marinkovic JM, Ilic MD, Kocev NI. Diet and prostate cancer: a case-control study. Eur J Cancer 1997; 33: 101-7.
90. Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R, et al. Null association between prostate cancer and serum folate, vitamin B6, vitamin B12, and homocys-teine. Cancer Epidemiol Biomarkers Prev 2003; 12: 1271-2.
91. Bistulf G, VanDette E, Matsui SI, Smiraglia DJ. Mild folate defciency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol 2010; 8: 6.
92. Tomaszewski JJ, Cummings JL, Parwani AV, et al. Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate. Prostate 2011; 71: 1287-93.
93. Lucock M, Yates Z. Folic acid fortifcation: a double-edged sword. Curr Opin Clin Nutr Metab Care 2009; 12: 555-64.
94. Fillmore KM, Chikritzhs T, Stockwell T, Bostrom A, Pascal R. Alcohol use and prostate cancer: a meta-analy-sis. Mol Nutr Food Res 2009; 53: 240-55.
95. Pelucchi C, Galeone C, Talamini R, et al. Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol Biomarkers Prev 2005; 14: 944-8.
96. Stevens VL, Rodriguez C, Pavluck AL, McCullough ML, Thun MJ, Calle E. Folate nutrition and prostate cancer incidence in a large cohort of US men. Am J Epidemiol 2006; 163: 989-96.
97. Kobayashi LC, Limburg H, Miao Q, et al. Folate intake, alcohol consumption, and the methylenetetrahydrofo-late reductase (MTHFR) C677T gene polymorphism: in-fuence on prostate cancer risk and interactions. Front Oncol 2012; 2: 100.
98. Vidal AC, Grant DJ, Williams CD, et al. Associations between intake of folate, methionine, and vitamins B12, B6 and prostate cancer risk in American veterans. J Cancer Epidemiol 2012; 2012: 957467.
99. de Vogel S, Meyer K, Fredriksen Å, et al. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk-a norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. Int J Epidemiol 2013; 42: 201-10.
100. Platz EA, Helzlsouer KJ. Selenium, zinc, and prostate cancer. Epidemiol Rev 2001; 23: 93-101.
101. Leitzmann M F, Stampfer MJ, Wu K, Colditz GA, Wil-lett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003; 95: 1004-7.
102. Gallus S, Foschi R, Negri E, et al. Dietary zinc and prostate cancer risk: a case-control study from Italy. Eur Urol 2007; 52: 1052-6.
103. Hong SH, Choi YS, Cho HJ, Lee JY, Hwang TK, Kim SW. Induction of apoptosis of bladder cancer cells by zinc-citrate compound. Korean J Urol 2012; 53: 800-6.
104. Hellemans G, Soumillion A, Proost P, et al. Metallo-thioneins in human kidneys and associated tumors. Nephron 1999; 83: 331-40.
105. Nemoto K, Kondo Y, Himeno S, et al. Modulation of telomerase activity by zinc in human prostatic and renal cancer cells. Biochem Pharmacol 2000; 59: 401-5.
106. Panel on Dietary Antioxidants and Related Compounds, Subcommittee on Upper Reference Levels of Nutrients, Subcommittee on Interpretation and Uses of DRIs, Standing Committee on the Scientifc Evaluation of Dietary Reference Intakes, Food and Nutrition Board; Institute of Medicine. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. Medicine Io. Washington, DC: The National Academy Press, 2000.
107. Stratton J, Godwin M. The efect of supplemental vitamins and minerals on the development of prostate cancer: a systematic review and meta-analysis. Fam Pract 2011; 28: 243-52.
108. Gaziano JM, Sesso HD, Christen WG, et al. Multivita-mins in the prevention of cancer in men: the physicians' health study II randomized controlled trial. JAMA 2012; 308: 1871-80.
109. Posadzki P, Lee MS, Onakpoya I, Lee HW, Ko BS, Ernst E. Dietary supplements and prostate cancer: a systematic review of double-blind, placebo-controlled randomised clinical trials. Maturitas 2013; 75: 125-30.
110. Zhang Y, Coogan P, Palmer JR, Strom BL, Rosenberg L. Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control 2009; 20: 691-8.
111. Zhang SM, Calle EE, Petrelli JM, Jacobs EJ, Thun MJ. Vitamin supplement use and fatal non-Hodgkin's lym-phoma among US men and women. Am J Epidemiol 2001; 153: 1064-70.
112. Hotaling JM, Wright JL, Pocobelli G, Bhatti P, Porter M P, White El. Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. J Urol 2011; 185: 1210-5.